-
2023-509029-29-00
5
2022-06-29
Familial Chylomicronemia Syndrome (FCS)
-
2023-508248-23-00
5
2021-11-26
Non-alcoholic steatohepatitis (NASH)
-
2024-510735-21-00
5
2021-11-26
Atherosclerotic cardiovascular disease (ASCVD)
-
2023-510319-20-00
5
2021-10-21
Gastroesophageal Adenocarcinoma (GEA)
-
2023-503990-39-00
5
2021-09-30
Estrogen Receptor-Positive, HER-2 negative Advanced Breast Cancer
-
2023-507963-20-00
5
2021-08-19
Metastatic Gastric Adenocarcinoma
-
2023-503995-26-00
5
2021-05-11
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
-
2023-507961-24-00
5
2021-04-19
High-Risk HER2-Positive Breast Cancer
-
2024-514434-20-00
5
2020-06-29
Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
-
2024-518318-25-00
5
2020-06-24
Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with C
-
2023-508292-37-00
5
2020-03-06
Cardiovascular Disease
-
2023-506827-26-00
5
2019-05-02
While it is well-established that long-term good glycaemic control wil
-
2024-511648-16-00
5
2019-01-04
Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Advanced Unresecta
-
2023-506994-36-00
5
2018-10-11
Ulcerative Colitis
-
2024-510967-41-00
5
2018-09-21
Metastatic colorectal cancer
-
2023-509923-42-00
4
2017-07-06
HER2- positive breast cancer
-
2023-507193-40-00
5
2025-01-16
Moderate to Severe Plaque Psoriasis
-
2023-509644-10-00
9
2024-06-27
Advanced Non-small Cell Lung Cancer
-
2022-502653-34-01
11
2024-05-30
Atopic dermatitis and moderate-to severe atopic hand eczema
-
2022-502481-24-00
4
2024-05-23
Chronic Rhinosinusitis without Nasal Polyps (CRSsNP)
-
2023-503911-14-00
4
2024-01-25
Psoriasis
-
2022-501418-69-00
5
2023-11-21
Acute Coronary Syndrome
-
2022-502227-22-00
4
2023-10-25
Autoimmune disease
-
2022-502647-35-00
4
2023-09-01
Non-alcoholic steatohepatitis